BeiGene Ltd ADR [ONC] stock is trading at $228.87, up 0.53%. An important factor to consider is whether the stock is rising or falling in short-term value. The ONC shares have gain 0.87% over the last week, with a monthly amount glided 26.70%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 18, 2024, and set its price target to $288. Macquarie started tracking the stock assigning a Outperform rating and suggested a price target of $259 on September 12, 2023. Jefferies initiated its recommendation with a Buy and recommended $287 as its price target on August 17, 2023. Citigroup started tracking with a Buy rating for this stock on July 17, 2023, and assigned it a price target of $275. In a note dated June 30, 2023, Bernstein downgraded an Mkt Perform rating on this stock and revised its target price from $335 to $196.
BeiGene Ltd ADR [ONC] stock has fluctuated between $126.97 and $248.16 over the past year. BeiGene Ltd ADR [NASDAQ: ONC] shares were valued at $228.87 at the most recent close of the market.
Analyzing the ONC fundamentals
BeiGene Ltd ADR [NASDAQ:ONC] reported sales of 3.32B for the trailing twelve months, which represents a growth of 28.20%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 226.24 points at the first support level, and at 223.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 232.50, and for the 2nd resistance point, it is at 236.13.
Ratios To Look Out For
For context, BeiGene Ltd ADR’s Current Ratio is 1.93. On the other hand, the Quick Ratio is 1.72. Considering the valuation of this stock, the price to sales ratio is 6.75, the price to book ratio is 7.10.
Transactions by insiders
Recent insider trading involved Wang Xiaodong, Chair, Scientific Advisory Brd, that happened on Feb 04 ’25 when 41760.0 shares were sold. Chair, Scientific Advisory Brd, Wang Xiaodong completed a deal on Jan 07 ’25 to sell 41760.0 shares. Meanwhile, Director XIAODONG WANG bought 0.13 million shares on Jan 07 ’25.
